The company states: “Kite, a Gilead (GILD) Company, announced results from a five-year follow-up analysis of ZUMA-5, a Phase 2 study of Yescarta in patients with relapsed/refractory non-Hodgkin lymphomas, or NHL, including follicular lymphoma or marginal zone lymphoma. The analysis demonstrated that after a median follow-up of more than five years, patients treated with Yescarta continued to experience durable response and long-term survival. The data were shared in an oral presentation during the 66th American Society of Hematology Annual Meeting and Exposition. In ZUMA-5, 159 patients were enrolled. At a median follow-up of 64.6 months (range, 32.3-81.4; FL: 65.7, MZL: 55.8), the overall response rate was 90% and the complete response, CR, was 75%. Among patients who achieved a CR, 58% remained in CR at the time of data cutoff. The median duration of response was 60.4 months with estimated 60-month DOR of 53.4%. Median progression-free survival, PFS, was 62.2 months. PFS rates at 60 months in patients with FL were consistent regardless of high-risk characteristics. Median time to next therapy was NR in all patients with NHL (95% CI, 38.6-NE; consistent by disease type), with a 60-month estimated rate of 53.3% (95% CI, 45.0-60.9; FL: 54.0%, MZL: 50.9%). At data cutoff, 55% of patients (n=87) were alive with no new anticancer therapy. The median overall survival, OS, was NR, and the 60-month OS estimate was 69.0% (95% CI, 60.8-75.8; FL: 68.9, MZL: 71.1). No new Yescarta-related safety signals emerged in the five-year analysis. One patient progressed after the data cutoff of the four-year analysis and no patients died of disease progression after the prior analysis. Among treated patients (n=152, 124 FL, 28 MZL), three new events not related to Yescarta were reported after the four-year analysis, including Grade 3 metastasis, Grade 1 bladder cancer, and Grade 4 myelodysplastic syndrome (a serious adverse event). One patient died of pneumonia, unrelated to Yescarta. At any time on trial, a total of 46 patients died, due to progressive disease (n=14), secondary malignancies (n=6), infections (n=11), or another or unknown cause (n=15).”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GILD:
- Gilead price target raised to $115 from $105 at Oppenheimer
- Arcellx, Gilead announce new data from iMMagine-1 study of anitocabtagene autole
- Gilead enters ADC option and license pact with Tubulis, sees dilution
- Gilead announces PURPOSE 2 trial data published in NEJM
- Gilead price target raised to $96 from $70 at UBS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
